13F HOLDINGS REPORT
Decheng Capital Management III (Cayman), LLC
Quarter ended Q3 2023 · Filed July 28, 2023 · Accession 0001104659-23-085148
Total Value
$318.8M
Positions
25
Other Managers
0
Confidential Omitted
No
Holdings (25)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Alpine Immune Sciences, Inc. | 010392595 | 6,708,288 | $69.0M | 21.63% |
| 2 | Zentalis Pharmaceuticals Inc. | ZNTL | 2,099,583 | $59.2M | 18.58% |
| 3 | ACELYRIN INC(NSM) | 00445A100 | 1,554,417 | $32.5M | 10.19% |
| 4 | 10x Genomics, Inc. | TXG | 359,554 | $20.1M | 6.30% |
| 5 | Pacific Biosciences of California, Inc. | 69404D108 | 1,463,872 | $19.5M | 6.11% |
| 6 | Arcus BioSciences, Inc. | RCUS | 869,790 | $17.7M | 5.54% |
| 7 | Illumnia, Inc. | ILMN | 80,859 | $15.2M | 4.76% |
| 8 | ROIVANT SCIENCES LTD | ROIV | 1,459,700 | $14.7M | 4.62% |
| 9 | PHATHOM PHARMACEUTICALS INC | PHAT | 850,000 | $12.2M | 3.82% |
| 10 | Argenx SE | ARGX | 27,429 | $10.7M | 3.35% |
| 11 | Horizon Therapeutics PLC | G46188101 | 78,900 | $8.1M | 2.55% |
| 12 | Terns Pharmaceuticals, Inc. | TERN | 714,285 | $6.2M | 1.96% |
| 13 | BeyondSpring Inc. | BYSI | 4,958,143 | $5.9M | 1.84% |
| 14 | Seagen Inc. | SE | 23,014 | $4.4M | 1.39% |
| 15 | Aura Biosciences, Inc. | AURA | 293,333 | $3.6M | 1.14% |
| 16 | Aadi Bioscience, Inc. | WHWK | 526,329 | $3.6M | 1.13% |
| 17 | Equillium Inc. | EQ | 4,447,308 | $3.3M | 1.05% |
| 18 | Cue Health Inc. | 229790100 | 8,980,909 | $3.3M | 1.04% |
| 19 | Mersana Therapeutics, Inc. | 59045L106 | 904,268 | $3.0M | 0.93% |
| 20 | AtriCure Inc. | ATRC | 46,259 | $2.3M | 0.72% |
| 21 | Scynexis Inc. | SCYX | 555,555 | $1.6M | 0.51% |
| 22 | Adicet Bio, Inc. | ACET | 505,668 | $1.2M | 0.39% |
| 23 | Apexigen, Inc. | 03759B102 | 1,894,551 | $814,278 | 0.26% |
| 24 | GeneDx Holdings Corp. | 81663L101 | 103,604 | $617,479 | 0.19% |
| 25 | NeuBase Therapeutics, Inc. | 64132K102 | 50,000 | $92,500 | 0.03% |